RNS Number : 8644T
BiVictriX Therapeutics PLC
26 June 2024
 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

Publication of 2023 Annual Report and Notice of AGM

 

Alderley Park, 26 June 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst eliminating treatment-related toxicities, announces that it has published and posted to shareholders the annual report and financial statements for the year ended 31 December 2023 ("Annual Report and Accounts"), and Notice of Annual General Meeting ("AGM").

 

BiVictriX will hold its AGM at the Company's registered office at Mereside Alderley Park, Alderley Edge, Manchester, SK10 4TG on 24 July 2024 at 3.00 p.m. (BST).

 

The Annual Report and Accounts and Notice of AGM are also available to view on, and download from, the Company's website at https://www.bivictrix.com/investor-centre.

 

ENDS

 

For more information, please contact:

 

BiVictriX Therapeutics plc


 

Tiffany Thorn, Chief Executive Officer

Michael Kauffman, Non-Executive Chairman

 

 

 

Email: info@bivictrix.com

 



 

SP Angel Corporate Finance LLP (NOMAD and Broker)

  Tel: +44 (0) 20 3470 0470


David Hignell, Caroline Rowe, Kasia Brzozowska (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)



 

Panmure Gordon (UK) Limited (Joint Broker)

 

  Tel: +44 (0) 20 7886 2500


Rupert Dearden/Freddy Crossley/Emma Earl

 

ICR Consilium


 

Mary-Jane Elliott, Namrata Taak,

Max Bennett, Emmalee Hoppe

Tel: +44 (0) 20 3709 5700

Email: Bivictrix@consilium-comms.com

 



 


 

About BiVictriX Therapeutics plc

 

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEANKSADSLEFA